---
title: 'Scientist, Lentiviral Vector Cell Line Development at Asimov'
canonical: 'https://feeny.ai/job/scientist-lentiviral-vector-cell-line-development-asimov-boston-vhtpf4a8bt9m'
type: 'job'
last_seen: '2026-10-16'
---

# Scientist, Lentiviral Vector Cell Line Development at Asimov

- **Company:** Asimov
- **Location:** Boston, MA
- **Compensation:** $120k–$130k
- **Employment:** full-time
- **Posted:** 2026-10-06
- **Last confirmed live:** 2026-10-16
- **Apply:** https://jobs.ashbyhq.com/asimov/f2c35e83-aa2c-48f1-96ea-ff2051971e35

## Job description

Our mission at Asimov is to advance humanity's ability to design living systems, enabling biotechnologies with outsized benefit to society. We're developing a mammalian synthetic biology platform––from cells to software––to enable the design and manufacture of next-generation therapeutics.

We are seeking a Scientist to join our Lentiviral Vector Cell Line Development team in Boston, MA. The ideal candidate has a proven track record developing lentiviral vector (LV) packaging and stable producer cell lines in an industry setting. In this role, you will play a central part in engineering stable producer cell lines for LV therapeutics while driving upstream process optimization and scale-up. This is a unique opportunity to work at a nimble, forward-thinking synthetic biology startup and help build the future of biological engineering.

About the Role:

- Perform Lentiviral vector stable producer cell line development processes including transfection, pool generation, cloning, characterization, and cell banking using state-of-the-art equipment.
- Perform assays to assess quantity, potency and infectivity of lentiviral vector preparations.
- Support innovation through development of novel workflows and applications.
- Support research projects to develop viral vector therapeutics with enhanced quality attributes such as infectivity, potency and/or cell targeting.
- Work effectively as part of a cross-functional team in support of the LV CLD platform and in collaboration with Synthetic Biology and Process Development teams.
- Contribute to process development efforts, including scale-up and characterization across Ambr15, Ambr250, and benchtop systems, as well as LV analytical assay development.
- Design experiments, analyze data, troubleshoot, and maintain detailed records.
- Represent LV CLD on project teams, making decisions for cell line development activities and effectively communicating results, progress and plans.

About You:

- You have a PhD in Biological Engineering, Chemical Engineering, Cell Biology, Molecular Biology, or a related field with 0-2 years of hands-on industry experience with Lentiviral vector production and cell line development in support of gene therapies; alternatively, a MS with 3-4 years or Bachelors with 6-8 years of this type of experience.
- Extensive experience performing viral transductions, including T-cell transduction assay, flow cytometry, and quantitative gene expression analyses (ddPCR or qPCR).
- Experience with Ambr15, Ambr250, and/or benchtop scale viral vector bioreactor processes.
- Experience with downstream purification of Lentiviral vectors, viral genome engineering, and/or host cell genome engineering related to virus production or producer cell line technologies is highly desired.
- Strong written and verbal communication skills required.

We're fueled by a vision to transform biological engineering into a fully-fledged engineering discipline. Should you join our team, you will grow with a constantly evolving organization and push the frontiers of synthetic biology. Company culture is key to Asimov, and ours is a culture of recombination; we believe that our mission can only be achieved by bringing together a diverse team with a mixture of backgrounds and perspectives.

## About Asimov

## Company Overview
- **One-liner**: Asimov builds an integrated platform of cells, genes, and software to program living systems, enabling the design and manufacture of advanced therapies.
- **Entity Type**: Private (Series B, raised $175M in January 2023)
- **Headquarters**: Boston, Massachusetts, USA (with a second office in Boulder, Colorado)
- **Founded**: 2017
- **Founders**: Alec Nielsen (CEO), Chris Voigt, Doug Densmore, Raja Srinivas

## Core Business
- **Primary industry/industries**: Synthetic biology, biotechnology, therapeutics manufacturing
- **Target customers**: B2B – biotech startups, mid-size biotechs, and large pharmaceutical companies (partnered with over 25 companies)
- **Mission or purpose statement**: “To radically advance humanity’s ability to design living systems, enabling biological technologies with outsized societal benefit.”

## Products & Services
- **Design Software**: Cloud-based CAD platform to design, simulate, and optimize genetic systems in different cell types.
- **Genetic Parts Library**: Over 1,000 experimentally validated genetic parts (transposases, expression vectors, inducible systems, tissue-specific promoters, etc.).
- **Host Cell Lines**: Engineered, highly characterized GMP host cells for therapeutic production (CHO, HEK293, etc.) with regulatory documentation.
- **LV Edge**: Stable cell lines and software tools for lentiviral titers up to 1E9 TU/mL.
- **AAV Edge**: End-to-end payload design and production achieving titers up to 6E15 vg/L.
- **RNA Edge**: Sequence design through wet-lab validation in weeks.
- **CHO Edge**: Genetic tools and data-driven models delivering titers of 8–12 g/L across modalities.
- **Platform Transfer & Full Service**: Two engagement models – customers use the platform in-house, or Asimov performs cell line development and process development at its Boston lab.

## Market Standing
- **Valuation/Market Cap**: Not disclosed
- **Key Metric**: Total funding of $205M; annual revenue of ~$4.0M (LinkedIn estimate)
- **Notable Investors/Partners**: Andreessen Horowitz (seed lead), Horizons Ventures (Series A lead), CPP Investments (Series B lead), DARPA (research support). Partners include 25+ biotechs and pharma companies.
- **Growth Signals**: 95 employees (25.8% YoY growth); raised $200M in Series B (Jan 2023); launched AI-driven 4th generation CHO Edge System with increased titer guarantee; expanding into RNA and cell therapy tools.

## Competitive Advantages
- Only company offering an end-to-end platform that integrates mammalian synthetic biology, computer-aided design, and machine learning.
- Proprietary library of 1,000+ well-characterized genetic parts and GMP-banked host cells.
- “We use our own platform every day” – internal R&D teams validate improvements before releasing to customers.
- Strong regulatory support (GMP documentation for host cells) that de-risks therapeutic development.

## Strategic Focus
- Deepen AI/ML integration into genetic design and cell line development.
- Expand platform to cover more therapeutic modalities (cell therapy, RNA therapy, biologics).
- Scale partnerships with large pharma while continuing to support early-stage biotechs.
- Build out the “first CAD platform for biology” to transition genetic engineering into a fully-fledged engineering discipline.

## Why Work Here
- **Culture**: “A culture of recombination” – interdisciplinary team of biologists, engineers, and ML scientists. Values include mission first, urgency, continuous learning, thoughtful communication, and avoiding local optima.
- **Work model**: Hybrid – employees engage in a combination of remote and on-site work (Cambridge, MA and Boulder, CO).
- **Perks & growth**: Built In profile highlights career growth, compensation & benefits, work-life balance, and stability. The company is actively hiring across roles (Staff Software Engineer, Principal Scientist, Sr. Scientist, Associate Director).
- **Impact**: Work at the cutting edge of synthetic biology, directly contributing to the design and manufacture of life-saving therapies.

## Sources
1. [asimov.com](https://www.asimov.com/)
2. [asimov.com/about](https://www.asimov.com/about)
3. [LinkedIn](https://www.linkedin.com/company/asimov)
4. [Built In](https://builtin.com/company/asimov)
5. [Careers Page](https://jobs.ashbyhq.com/asimov)

## Other roles at Asimov

- [Scientist, Viral Vector Process Development](https://feeny.ai/job/scientist-viral-vector-process-development-asimov-boston-1qsqy03f8zyb) — Boston, MA
- [Senior Scientist, Analytical Development](https://feeny.ai/job/senior-scientist-analytical-development-asimov-boston-9r1y790704fx) — Boston, MA
- [Senior Scientist, Lentiviral Vector Cell Line Development](https://feeny.ai/job/senior-scientist-lentiviral-vector-cell-line-development-asimov-boston-fdjvx16748gc) — Boston, MA
- [Senior Program Manager](https://feeny.ai/job/senior-program-manager-asimov-boston-9pe8sjrfnxdw) — Boston, MA
- [Principal Scientist, Biologics Cell Line Development](https://feeny.ai/job/principal-scientist-biologics-cell-line-development-asimov-boston-zc098zf7xer4) — Boston, MA
- [Senior Scientist, Biologics Cell Line Development](https://feeny.ai/job/senior-scientist-biologics-cell-line-development-asimov-boston-5ypxr524ze78) — Boston, MA